Perrigo Co. Plc (PRGO)

70.40
0.96 1.38
NYSE : Health Technology
Prev Close 69.44
Open 69.51
Day Low/High 69.17 / 70.91
52 Wk Low/High 67.53 / 95.93
Volume 1.95M
Avg Volume 1.24M
Exchange NYSE
Shares Outstanding 136.83M
Market Cap 9.50B
EPS 0.80
P/E Ratio 41.59
Div & Yield 0.76 (1.01%)
Trade-Ideas: Perrigo (PRGO) Is Today's Post-Market Leader Stock

Trade-Ideas: Perrigo (PRGO) Is Today's Post-Market Leader Stock

Trade-Ideas LLC identified Perrigo (PRGO) as a post-market leader candidate

Valeant 'Received Bid Proposal' From Takeda, TPG

Valeant 'Received Bid Proposal' From Takeda, TPG

The proposal came before former Perrigo boss Papa was installed at the helm of the troubled drugs maker.

Valeant Works to Restore Accounting Reputation

Valeant Works to Restore Accounting Reputation

Former Tyco International executive Sam Eldessouky will take on the role of controller at the the embattled pharmaceutical company at the end of the month.

Valeant Filing: CEO to Earn $1.5M, More if He Meets Goals

Valeant Filing: CEO to Earn $1.5M, More if He Meets Goals

Valeant is working to rebrand itself and it's starting with paying CEO Joe Papa less than his predecessor.

Valeant to Evaluate Sales of Noncore Assets

Valeant to Evaluate Sales of Noncore Assets

Newly appointed CEO Joseph Papa says at the UBS Global Healthcare Conference that the drugmaker will look to pare its debt load through divestitures.

Investors Comforted as Perrigo Sticks to Forecast

Investors Comforted as Perrigo Sticks to Forecast

As the pharma company's investors remain in "show me mode" with a new CEO at the helm, its maintained guidance may have offset revised earning results.

Monsanto, Amazon and Apple: Doug Kass' Views

Monsanto, Amazon and Apple: Doug Kass' Views

Doug Kass shares his thoughts on shorting financials, and wonders if it will be a Monsanto merger Monday.

Papa's New Bag; Sears About to Become a Swan: Best of Kass

Papa's New Bag; Sears About to Become a Swan: Best of Kass

In highlights from this week's trading diary and posts, Kass discusses Joseph Papa's new gig at Valeant and how Sears is about to become a swan.

Perrigo (PRGO) Stock Price Target Reduced at Leerink

Perrigo (PRGO) Stock Price Target Reduced at Leerink

Perrigo’s (PRGO) new management faces problems at the pharmaceutical company that may not be easily fixed, according to Leerink analysts.

Mylan Tacks On Another Generics Company on the Cheap

Mylan Tacks On Another Generics Company on the Cheap

The company is expanding into the generics drug business.

Pre-Market Laggard: Perrigo (PRGO)

Pre-Market Laggard: Perrigo (PRGO)

Trade-Ideas LLC identified Perrigo (PRGO) as a pre-market laggard candidate

Valeant Whipsawed by Criticism Over Drug Prices and New Leadership

The drugmaker's quest to rebrand itself as a patient-first company is foundering over renewed controversy over drug pricing.

New Regime at Perrigo Provides Reason to Invest

New Regime at Perrigo Provides Reason to Invest

To investors' relief, Perrigo's new leadership reaffirmed the pharmaceuticals company's 2016 calendar outlook on Thursday.

Teva Should Break Out of Droopy Drug Pack

Despite an earnings beat and upbeat outlook, its stock has suffered with other drug makers.

What to Look For When Perrigo (PRGO) Reports Q1 Results

What to Look For When Perrigo (PRGO) Reports Q1 Results

Perrigo (PRGO) is scheduled to release its 2016 first quarter earnings on Thursday before the market open.

There's a Lot to Be Resolved on Perrigo

It reports tomorrow, but where will the company ultimately fall this quarter?

Jim Cramer -- Valeant Has Too Many 'What Ifs' Right Now

Jim Cramer -- Valeant Has Too Many 'What Ifs' Right Now

New Chairman and CEO Joe Papa can't stop the world from gunning for Valeant.

Cramer Talks Debt, Pipeline With Valeant CEO

Cramer Talks Debt, Pipeline With Valeant CEO

TheStreet's founder shares his thoughts after his one-on-one interview with Valeant's new chairman and CEO.

Cramer: The World Is Gunning for Valeant

And Joe Papa can't stop the world. 

Jim Cramer's Top Takeaways: Valeant, Kimco Realty, Simon Property Group, Integrated Device Technology

Jim Cramer's Top Takeaways: Valeant, Kimco Realty, Simon Property Group, Integrated Device Technology

Cramer is remaining cautious on Valeant but is bullish on Integrated Device Technology.

Jim Cramer's 'Mad Money' Recap: What Was Hated Friday Is Loved Monday

Jim Cramer's 'Mad Money' Recap: What Was Hated Friday Is Loved Monday

This market changes on a dime, Cramer says. A market without conviction can be tricky.

Valeant's Accounting Practices Raise Uncertainty, Cramer Says

Valeant's Accounting Practices Raise Uncertainty, Cramer Says

The fact that Valeant will report its Q1 financials ahead of the June 10 deadline shouldn't appease investors, according to TheStreet's founder.

Jim Cramer -- Why Allergan Is So Beaten Down Ahead of Earnings

Jim Cramer -- Why Allergan Is So Beaten Down Ahead of Earnings

Despite an incredible CEO, solid businesses and a big deal with Teva, Allergan has seen its shares continue to struggle. Jim Cramer looks at why.

Jim Cramer: Allergan CEO Brent Saunders Is Doing a Great Job

Jim Cramer: Allergan CEO Brent Saunders Is Doing a Great Job

Jim Cramer thinks Allergan CEO Brent Saunders has put together a world class company.

Cramer on Valeant’s New CEO Joseph Papa

Cramer on Valeant’s New CEO Joseph Papa

New Valeant CEO and former Perrigo CEO Joseph Papa will be joining TheStreet's Jim Cramer on "Mad Money" tonight.

Jim Cramer's 'Mad Money' Recap: Here's This Week's Game Plan

Jim Cramer's 'Mad Money' Recap: Here's This Week's Game Plan

Cramer says he's looking forward to another week of earnings to see which bull markets are alive and well.

New Valeant CEO Acknowledges 'Mistakes' In Drug Prices, Forms Oversight Panel

New Valeant CEO Acknowledges 'Mistakes' In Drug Prices, Forms Oversight Panel

Three days after taking over as CEO, Papa seeks to calm investors by setting up patent access and pricing committee for drugs

3 Drugs Stocks Pushing The Industry Higher

3 Drugs Stocks Pushing The Industry Higher

TheStreet highlights 3 stocks pushing the drugs industry higher today.

Perrigo Bears Turn Aggressive

Perrigo could have an oversold bounce at any time as bears turn aggressive, but nothing right now indicates a price bottom.

CAT, IBM, KO: Jim Cramer's Views

CAT, IBM, KO: Jim Cramer's Views

Jim Cramer shares his views on pajama traders and the need for new leadership in the market. Caterpillar, IBM and Coca-Cola are among the stocks discussed here.

TheStreet Quant Rating: D+ (Sell)